Allucent Strengthens Executive Team to Drive Biopharma Innovation

 Allucent, a global, science-centric CRO focused on partnering with small and mid-sized biopharmaceutical innovators, announced the expansion of its executive team with three proven industry leaders. Patrick Phillips has joined as chief operating officer (COO), Rachel Page as chief commercial officer (CCO), and Nate Thompson as chief information officer (CIO). Their combined decades of CRO and biopharma leadership and proven specialized expertise further strengthen Allucent's ability to scale, innovate, and deliver unique value for small and mid-sized companies, driving tomorrow's breakthrough therapies.

In today's competitive life sciences market, speed, precision, and informed decision-making are critical. Allucent's approach — global reach, nimble methodology, and A-Team drug development experts — helps biopharma businesses advance programs efficiently, reduce risk, and maximize value from the start. The company's new appointments further strengthen its operational delivery and trusted partnerships with its clients.

"I'm thrilled to welcome Patrick, Rachel, and Nate to Allucent as we enter our next chapter," said Paula Brown Stafford, CEO of Allucent. "They bring the right mix of expertise and passion at exactly the right time. Each has a proven track record in high-growth CRO and/or biopharma environments and a drive to advance the transformative science coming from small and mid-sized biopharmaceutical companies. Their leadership will accelerate our momentum, strengthen our capabilities, and reinforce Allucent's position as the partner of choice for biopharma innovators working to bring new therapies to patients."